Nigral endothelial dysfunction, homocysteine, and Parkinson's disease.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 10408491.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We found increased levels of atherosclerosis-inducing homocysteine in parkinsonian patients with long-term application of levodopa compared with previously untreated parkinsonian patients and controls. We conclude that antiparkinsonian treatment with levodopa promotes occurrence of vascular disease in Parkinson's disease.
Medical subject headings
- Antiparkinson Agents
- Homocysteine
- Levodopa
- Parkinson Disease
- Substantia Nigra
- Vascular Diseases